Rituximab in the treatment of non-Hodgkin’s lymphoma

References

• AksoySAbaliHKilickapSErmanM2006Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin’s lymphoma patientClin Lab Haematol28211416706940
   PubMedGoogle Scholar
• BenkerrouMJaisJPLeblondV1998Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcomeBlood923137479787149
   PubMed Web of Science ®Google Scholar
• BerguaJMCabreraCArtetaEG2008Rituximab in CD20 positive multiple myelomaLeukemia221082317972949
   PubMed Web of Science ®Google Scholar
• BoueFGabarreJGisselbrechtC2006Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin’s lymphomaJ Clin Oncol244123816896005
   PubMed Web of Science ®Google Scholar
• BuskeCHosterEDreylingMThe addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma – results of a randomized trial of the German Low Grade Lymphoma Study Group (GLSG)LeukemiaIn press
   Web of Science ®Google Scholar
• ByrdJCMurphyTHowardRS2001Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicityJ Clin Oncol1921536411304767
   PubMed Web of Science ®Google Scholar
• CartronGZhao-YangLBaudardM2008Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II studyJ Clin Oncol2627253118427151
   PubMed Web of Science ®Google Scholar
• CartronGDacheuxLSallesG2002Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcgamma RIIIa geneBlood99754811806974
   PubMed Web of Science ®Google Scholar
• ChenBJEpsteinJ1996Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cellsBlood87197268634446
   PubMed Web of Science ®Google Scholar
• ChoquetSOertelSLeblondV2007Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with cautionAnn Hematol8659960717522862
   PubMed Web of Science ®Google Scholar
• ChoquetSLeblondVHerbrechtR2006aEfficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 studyBlood1073053716254143
   PubMed Web of Science ®Google Scholar
• ClynesRATowersTLPrestaLG2000Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targetsNat Med6443610742152
   PubMed Web of Science ®Google Scholar
• CoiffierB2005State-of-the-art therapeutics: diffuse large B-cell lymphomaJ Clin Oncol2363879316155024
   PubMed Web of Science ®Google Scholar
• CoiffierBHaiounCKettererN1998Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II studyBlood921927329731049
   PubMed Web of Science ®Google Scholar
• CoiffierBLepageEBriereJ2002CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphomaN Engl J Med3462354211807147
   PubMed Web of Science ®Google Scholar
• ColombatPBrousseNMorschhauserF2006Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analyses with extended follow-up of 7 yearsASH Annual Meeting Abstracts108486
   Google Scholar
• ColombatPSallesGBrousseN2001Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluationBlood97101611133748
   PubMed Web of Science ®Google Scholar
• ConconiAMartinelliGThieblemontC2003Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT typeBlood1022741512842999
   PubMed Web of Science ®Google Scholar
• CzuczmanM1999CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphomaSemin Oncol26889610561023
   PubMed Web of Science ®Google Scholar
• CzuczmanMSThallAWitzigTE2005Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphomaJ Clin Oncol234390815994148
   PubMed Web of Science ®Google Scholar
• CzuczmanMSWeaverRAlkuzwenyB2004Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-upJ Clin Oncol224711615483015
   PubMed Web of Science ®Google Scholar
• DavisTAGrillo-LopezAJWhiteCA2000Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatmentJ Clin Oncol1831354310963642
   PubMed Web of Science ®Google Scholar
• DiJosephJFGoadMEDougherMM2004Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphomaClin Cancer Res108620915623646
   PubMed Web of Science ®Google Scholar
• DiJosephJFDougherMMKalyandrugLB2006Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic Immunoconjugate of calicheamicin, and rituximab against non-Hodgkin’s B-cell lymphomaClin Cancer Res12242916397048
   PubMed Web of Science ®Google Scholar
• DimopoulosMAZervasCZomasA2002Treatment of Waldenstrom’s macroglobulinemia with rituximabJ Clin Oncol2023273311981004
   PubMed Web of Science ®Google Scholar
• DimopoulosMAAnagnostopoulosAKyrtsonisMC2007Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamideJ Clin Oncol253344917577016
   PubMed Web of Science ®Google Scholar
• DregerPRiegerMSeyfarthB2007Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcomeHaematologica9242917229634
   PubMed Web of Science ®Google Scholar
• EntingRHDemopoulosADeAngelisLM2004Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomideNeurology63901315365145
   PubMed Web of Science ®Google Scholar
• FerreriAJAbreyLEBlayJY2003Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002J Clin Oncol2124071412805341
   PubMed Web of Science ®Google Scholar
• FlohrTHessGKolbeK2002Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHLBone Marrow Transplant297697512040475
   PubMed Web of Science ®Google Scholar
• Foreno-TorresAFurmanRRRosenblattJD2006A humanized antibody against CD40 (SGN-40) is well tolerated and active in non-Hodgkin`s lymphoma (NHL): results of a phase I study7534
   Google Scholar
• ForstpointnerRDreylingMReppR2004The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood10430647115284112
   PubMed Web of Science ®Google Scholar
• ForstpointnerRUnterhaltMDreylingM2006Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)Blood1084003816946304
   PubMed Web of Science ®Google Scholar
• GertzMARueMBloodE2004Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98)Leuk Lymphoma4520475515370249
   PubMed Web of Science ®Google Scholar
• GhielminiMSchmitzSFCogliattiS2005aEffect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)J Clin Oncol237051115598978
   PubMed Web of Science ®Google Scholar
• GhielminiMSchmitzSFCogliattiSB2004Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 scheduleBlood10344162314976046
   PubMed Web of Science ®Google Scholar
• GhielminiMNegrettiLLerchE2005bInfusion speed-escalation trial to give full-dose rituximab in one hour without steroids pre-medicationASH Annual Meeting Abstracts1062451
   Google Scholar
• GisselbrechtCSchmitzNMounierN2007R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by stem cell transplantation and maintenance treatment with rituximab or not: first interim analysis on 200 patients. CORAL StudyASH Annual Meeting Abstracts110517
   Google Scholar
• GoldbergSLPecoraALAlterRS2002Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximabBlood991486811830505
   PubMed Web of Science ®Google Scholar
• GolombHMFeferAGoldeDW1987Sequential evaluation of alpha-2b-interferon treatment in 128 patients with hairy cell leukemiaSemin Oncol141373589701
   PubMed Web of Science ®Google Scholar
• GolombHM2008Hairy cell leukemia: treatment successes in the past 25 yearsJ C Oncol2626079
   PubMed Web of Science ®Google Scholar
• GorschluterMZiskeCGlasmacherA2001Current clinical and laboratory strategies to augment the efficacy of immunotherapy in multiple myelomaClin Cancer Res7219520411489792
   PubMed Web of Science ®Google Scholar
• GreverMKopeckyKFoucarMK1995Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup studyJ Clin Oncol13974827707126
   PubMed Web of Science ®Google Scholar
• HabermannTMWellerEAMorrisonVA2006Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphomaJ Clin Oncol243121716754935
   PubMed Web of Science ®Google Scholar
• HainsworthJDLitchySShafferDW2005Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma – randomized phase II trial of the Minnie Pearl Cancer Research NetworkJ Clin Oncol2310889515657401
   PubMed Web of Science ®Google Scholar
• HainsworthJDLitchySBartonJH2003Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research NetworkJ Clin Oncol2117465112721250
   PubMed Web of Science ®Google Scholar
• HarrisNLJaffeESSteinH1994A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study GroupBlood841361928068936
   PubMed Web of Science ®Google Scholar
• HeroldMHaasASrockS2007Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology StudyJ Clin Oncol2519869217420513
   PubMed Web of Science ®Google Scholar
• HessGFlohrTKolbeK2006Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin’s lymphomaAnn Hematol857697916896912
   PubMed Web of Science ®Google Scholar
• HiddemannWKnebaMDreylingM2005Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood10637253216123223
   PubMed Web of Science ®Google Scholar
• HoerrALGaoFHidalgoJ2004Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin’s lymphomaJ Clin Oncol224561615542807
   PubMed Web of Science ®Google Scholar
• HuhnDvon SchillingCWilhelmM2001Rituximab therapy of patients with B-cell chronic lymphocytic leukemiaBlood9813263111520778
   PubMed Web of Science ®Google Scholar
• JensenMWinklerUManzkeO1998Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8), rituximabAnn Hematol7789919760161
   PubMed Web of Science ®Google Scholar
• KalpadakisCPangalisGADimopoulouMN2007Rituximab monotherapy is highly effective in splenic marginal zone lymphomaHematol Oncol251273117514771
   PubMed Web of Science ®Google Scholar
• KaplanLDLeeJYAmbinderRF2005Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010Blood10615384315914552
   PubMed Web of Science ®Google Scholar
• KayNEGeyerSMCallTG2007Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaBlood1094051117008537
   PubMed Web of Science ®Google Scholar
• KeatingMJO’BrienSAlbitarM2005Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemiaJ Clin Oncol2340798815767648
   PubMed Web of Science ®Google Scholar
• KewalramaniTZelenetzADNimerSD2004Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphomaBlood1033684314739217
   PubMed Web of Science ®Google Scholar
• KohlerGMilsteinC1975Continuous cultures of fused cells secreting antibody of predefined specificityNature25649571172191
   PubMed Web of Science ®Google Scholar
• LauriaFLenociMAnninoL2001Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemiaHaematologica8610465011602410
   PubMed Web of Science ®Google Scholar
• LemieuxBBouafiaFThieblemontC2004Second treatment with rituximab in B-cell non-Hodgkin’s lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon SudHematol J54677115570286
   PubMedGoogle Scholar
• LenzGDreylingMHosterE2005Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)J Clin Oncol2319849215668467
   PubMed Web of Science ®Google Scholar
• LeonardJPColemanMKetasJC2003Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin’s lymphomaJ Clin Oncol213051912837807
   PubMed Web of Science ®Google Scholar
• LeonardJPColemanMKetasJC2004Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin’s lymphoma: phase I/II clinical trial resultsClin Cancer Res1053273415328168
   PubMed Web of Science ®Google Scholar
• MagniMDi NicolaMDevizziL2000Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusionBlood96864910910898
   PubMed Web of Science ®Google Scholar
• MaloneyDGBrownSCzerwinskiDK1992Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cellsBlood801502101520877
   PubMed Web of Science ®Google Scholar
• MaloneyDGLilesTMCzerwinskiDK1994Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphomaBlood842457667522629
   PubMed Web of Science ®Google Scholar
• MarcusRImrieKBelchA2005CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphomaBlood10514172315494430
   PubMed Web of Science ®Google Scholar
• MarcusRESolal-CelignyPImrieK2006MabThera (rituximab) plus cyclophosphamide, vincristine and prednisone (cvp) chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkin’s lymphoma (NHL)ASH Annual Meeting Abstracts108481
   Google Scholar
• MartinelliGLaszloDFerreriAJM2005Clinical activity of rituximab in gastric marginal zone non-Hodgkin’s lymphoma resistant to or not eligible for anti-Helicobacter pylori therapyJ Clin Oncol2319798315668468
   PubMed Web of Science ®Google Scholar
• MatsuiWHuffCAWangQ2004Characterization of clonogenic multiple myeloma cellsBlood1032332614630803
   PubMed Web of Science ®Google Scholar
• MatteucciPMagniMDiNM2002Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibodyBlood1001104512150156
   PubMed Web of Science ®Google Scholar
• McLaughlinPGrillo-LopezAJLinkBK1998bRituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment programJ Clin Oncol162825339704735
   PubMed Web of Science ®Google Scholar
• MeleAPulsoniABiancoE2003Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control studyBlood102996912714514
   PubMed Web of Science ®Google Scholar
• MicallefINMaurerMJNikcevichDA2008A phase II study of epratzumumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphomap. abstr. 8500
   Google Scholar
• MoreauPVoillatLBenboukherL2007Rituximab in CD20 positive multiple myelomaLeukemia21835617268523
   PubMed Web of Science ®Google Scholar
• MorgnerASchmelzRThiedeC2007Therapy of gastric mucosa associated lymphoid tissue lymphomaWorld J Gastroenterol1335546617659705
   PubMed Web of Science ®Google Scholar
• MounierNBriereJGisselbrechtC2006and Groupe d’Etude des Lymphomes de l’Adulte. Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphomaHaematologica91715616670080
   PubMed Web of Science ®Google Scholar
• MounierNBriereJGisselbrechtC2003Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)Blood10142798412576316
   PubMed Web of Science ®Google Scholar
• MounierNSpinaMGisselbrechtC2007Modern management of non-Hodgkin lymphoma in HIV-infected patientsBr J Haematol1366859817229246
   PubMed Web of Science ®Google Scholar
• NadlerLMStashenkoPHardyR1980Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigenCancer Res403147547427932
   PubMed Web of Science ®Google Scholar
• NievaJBethelKSavenA2003Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemiaBlood102810312663446
   PubMed Web of Science ®Google Scholar
• NuckelHMellerDSteuhlKP2004Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctivaEur J Haematol732586215347312
   PubMed Web of Science ®Google Scholar
• O’BrienSMKantarjianHThomasDA2001Rituximab dose-escalation trial in chronic lymphocytic leukemiaJ Clin Oncol1921657011304768
   PubMed Web of Science ®Google Scholar
• OwenRGTreonSPAl-KatibA2003Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s MacroglobulinemiaSemin Oncol30110512720118
   PubMed Web of Science ®Google Scholar
• OzgonenelBMoonkaDSavasanS2006Fulminant hepatitis B following rituximab therapy in a patient with Evans syndrome and large B-cell lymphomaAm J Hematol8130216550511
   PubMed Web of Science ®Google Scholar
• PerceauGDirisNEstinesO2006Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphomaBr J Dermatol1551053617034541
   PubMed Web of Science ®Google Scholar
• PfreundschuhMHoADCavallin-StahlE2008aPrognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) studyLancet Oncol94354418400558
   PubMed Web of Science ®Google Scholar
• PfreundschuhMSchubertJZiepertM2008bSix versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 B-cell lymphomas: a randomised controlled trial (RICOVER-60)Lancet Oncol91051618226581
   PubMed Web of Science ®Google Scholar
• PfreundschuhMTrumperLOsterborgA2006CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT. Group)Lancet Oncol73799116648042
   PubMed Web of Science ®Google Scholar
• PfreundschuhMZeynalovaSPoeschelV2007Dose-dense rituximab improves outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL): results of the DENSE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)ASH Annual Meeting Abstracts110789
   Google Scholar
• PhilipTGuglielmiCHagenbeekA1995Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphomaN Engl J Med333154057477169
   PubMed Web of Science ®Google Scholar
• PilarskiLMHippersonGSeebergerK2000Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID miceBlood9510566510648422
   PubMed Web of Science ®Google Scholar
• PileriSSabattiniEPoggiS1994Bone-marrow biopsy in hairy cell leukaemia (HCL) patients. Histological and immunohistological analysis of 46 cases treated with different therapiesLeuk Lymphoma14Suppl 167717820056
   PubMed Web of Science ®Google Scholar
• PiroLDCarreraCJCarsonDA1990Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosineN Engl J Med191117211969613
   PubMed Web of Science ®Google Scholar
• PressOWAppelbaumFLedbetterJA1987Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomasBlood69584913492224
   PubMed Web of Science ®Google Scholar
• RaiKRDaveyFPetersonB1995Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group BLeukemia91116207630181
   PubMed Web of Science ®Google Scholar
• RavandiFJorgensenJLO’BrienSM2006Eradication of minimal residual disease in hairy cell leukemiaBlood10746586216497968
   PubMed Web of Science ®Google Scholar
• RileyJKSliwkowskiMX2000CD20: a gene in search of a function1724
   Google Scholar
• RobakTSmolewskiPCebulaB2007Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemiaEur J Haematol791071317635235
   PubMed Web of Science ®Google Scholar
• RobillardNvet-LoiseauHGarandR2003CD20 is associated with a small mature plasma cell morphology and t(11–14) in multiple myelomaBlood1021070112702507
   PubMed Web of Science ®Google Scholar
• RomagueraJEFayadLRodriguezMA2005High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabineJ Clin Oncol2370132316145068
   PubMed Web of Science ®Google Scholar
• RottenburgerCKielKBosingT1999Clonotypic CD20+ and CD19++ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantationBr J Haematol1065455210460621
   PubMed Web of Science ®Google Scholar
• RubensteinJLFridlyandJAbreyL2007Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphomaJ Clin Oncol251350617312328
   PubMed Web of Science ®Google Scholar
• RuleSBurtonCRossM2005Combination with or without Rituximab in patients with untreatd mantle cell lymphoma
   Google Scholar
• RummelMJAl-BatranSEKimSZ2005Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphomaJ Clin Oncol233383915908650
   PubMed Web of Science ®Google Scholar
• SallesGAFoussardCNicolasM2004Rituximab added {alpha}IFN+CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: to first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patientsASH Annual Meeting Abstracts104160
   Google Scholar
• SallesGAMounierNde GuibertS2007Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: final Analysis of the GELA-GOELAMS FL2000 study with a 5-year follow-upASH Annual Meeting Abstracts110792
   Google Scholar
• SchulzHPelsHSchmidt-WolfI2004Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximabHaematologica897535415194546
   PubMed Web of Science ®Google Scholar
• ShahGDYahalomJCorreaDD2007Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphomaJ Clin Oncol254730517947720
   PubMed Web of Science ®Google Scholar
• SieniawskiMStaakOGlossmannJP2007Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphomaAnn Hematol861071517103169
   PubMed Web of Science ®Google Scholar
• SmithMR2003Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistanceOncogene2273596814576843
   PubMed Web of Science ®Google Scholar
• SparanoJA2007HIV-associated lymphoma: the evidence for treating aggressively but with cautionCurr Opin Oncol194586317762571
   PubMed Web of Science ®Google Scholar
• SpiersAMooreDCassilethP1987Pemissions in hairy cell leukemia with pentostatin (2`deoxycoformycin)N Engl J Med316825302434850
   PubMed Web of Science ®Google Scholar
• StockmeyerBDechantMvan EgmondM2000Triggering FC{alpha}-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapyJ Immunol16559546111067958
   PubMed Web of Science ®Google Scholar
• TamCSO’BrienSWierdaW2008Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemiaBlood1129758018411418
   PubMed Web of Science ®Google Scholar
• TarellaCZanniMMagniM2008Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi surveyJ Clin Oncol2631667518490650
   PubMed Web of Science ®Google Scholar
• ThieblemontCFelmanPBergerF2002Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patientsClin Lymphoma341712141954
   PubMedGoogle Scholar
• ThieblemontCFelmanPCallet-BauchuE2003Splenic marginal-zone lymphoma: a distinct clinical and pathological entityLancet Oncol49510312573351
   PubMed Web of Science ®Google Scholar
• ThomasDAFaderlSO’BrienS2006Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemiaCancer10615698016502413
   PubMed Web of Science ®Google Scholar
• ThomasDAO’BrienSBueso-RamosC2003Rituximab in relapsed or refractory hairy cell leukemiaBlood10239061112816862
   PubMed Web of Science ®Google Scholar
• TreonSPAgusDBLinkB2001CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom’s macroglobulinemiaJ Immunother242729
   Web of Science ®Google Scholar
• TreonSPEmmanouilidesCKimbyE2005Extended rituximab therapy in Waldenstrom’s macroglobulinemiaAnn Oncol16132815598950
   PubMed Web of Science ®Google Scholar
• TreonSPPilarskiLMBelchAR2002CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applicationsJ Immunother25728111924912
   PubMed Web of Science ®Google Scholar
• TsutsumiYKanamoriHMoriA2005Reactivation of hepatitis B virus with rituximabExpert Opin Drug Saf459960815934864
   PubMedGoogle Scholar
• van OersMHKlasaRMarcusRE2006bRituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin’s lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trialBlood108329530116873669
   PubMed Web of Science ®Google Scholar
• VoseJMLinkBKGrossbardML2001Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphomaJ Clin Oncol193899711208830
   PubMed Web of Science ®Google Scholar
• WierdaWO’BrienSWenS2005Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemiaJ Clin Oncol234070815767647
   PubMed Web of Science ®Google Scholar
• WongET2005Management of central nervous system lymphomas using monoclonal antibodies: challenges and opportunitiesClin Cancer Res1177151s7
   Web of Science ®Google Scholar
• WotherspoonACOrtiz-HidalgoCFalzonMR1991aHelicobacter pylori-associated gastritis and primary B-cell gastric lymphomaLancet338117561682595
   PubMed Web of Science ®Google Scholar
• YamanakaRMoriiKShinboY2008Results of treatment of 112 cases of primary CNS lymphomaJpn J Clin Oncol383738018413337
   PubMed Web of Science ®Google Scholar
• YangHRosoveMHFiglinRA1999Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemiaAm J Hematol622475010589082
   PubMed Web of Science ®Google Scholar
• ZinzaniPLAlinariLStefoniV2005Rituximab in primary conjunctiva lymphomaLeuk Res29107815541482
   PubMed Web of Science ®Google Scholar
• ZinzaniPLPulsoniAPerrottiA2004Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphomaJ Clin Oncol2226546115159414
   PubMed Web of Science ®Google Scholar